Financial Ratios Pure Health Holding
Stocks
PUREHEALTH
AEE01362P238
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.250 AED | 0.00% |
|
-0.44% | -11.76% |
| 01/05 | UAE Stocks in Green as US-Iran War Risks Resurface | MT |
| 01/05 | Pure Health remains well positioned to deliver sustainable growth | RE |
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
Profitability | ||||
Return on Assets | - | 3.59 | 4.25 | 3.15 |
Return on Total Capital | - | 6.01 | 6.26 | 4.72 |
Return On Equity % | - | 7.05 | 9.59 | 10.62 |
Return on Common Equity | - | 7.05 | 9.57 | 10.53 |
Margin Analysis | ||||
Gross Profit Margin % | 38.36 | 15.6 | 25.67 | 24.65 |
SG&A Margin | 19.47 | 23.02 | 18.02 | 17.48 |
EBITDA Margin % | 33.5 | 13.54 | 13.46 | 12.92 |
EBITA Margin % | 31.95 | 10.1 | 11.05 | 10.37 |
EBIT Margin % | 31.18 | 9.16 | 10.1 | 9.76 |
Income From Continuing Operations Margin % | 34.51 | 5.88 | 6.64 | 7.4 |
Net Income Margin % | 29.89 | 5.88 | 6.62 | 7.33 |
Net Avail. For Common Margin % | 29.89 | 5.88 | 6.62 | 7.33 |
Normalized Net Income Margin | 14.64 | 5.27 | 4.24 | 4.84 |
Levered Free Cash Flow Margin | - | 7.63 | 9.51 | 7.82 |
Unlevered Free Cash Flow Margin | - | 8.08 | 11.51 | 9.77 |
Asset Turnover | ||||
Asset Turnover | - | 0.63 | 0.67 | 0.52 |
Fixed Assets Turnover | - | 5.1 | 2.98 | 1.59 |
Receivables Turnover (Average Receivables) | - | 5.82 | 4.33 | 3.83 |
Inventory Turnover (Average Inventory) | - | 20.63 | 19.96 | 15.83 |
Short Term Liquidity | ||||
Current Ratio | 1.62 | 2.26 | 1.88 | 1.35 |
Quick Ratio | 1.41 | 1.96 | 1.66 | 1.15 |
Operating Cash Flow to Current Liabilities | 0.4 | 0.31 | 0.34 | 0.33 |
Days Sales Outstanding (Average Receivables) | - | 62.73 | 84.49 | 95.23 |
Days Outstanding Inventory (Average Inventory) | - | 17.69 | 18.33 | 23.06 |
Average Days Payable Outstanding | - | 33.25 | 28.12 | 149.41 |
Cash Conversion Cycle (Average Days) | - | 47.17 | 74.71 | -31.12 |
Long Term Solvency | ||||
Total Debt/Equity | 16.86 | 12.18 | 72.82 | 99.47 |
Total Debt / Total Capital | 14.42 | 10.86 | 42.14 | 49.87 |
LT Debt/Equity | 15.5 | 11.86 | 71.13 | 94.47 |
Long-Term Debt / Total Capital | 13.26 | 10.58 | 41.16 | 47.36 |
Total Liabilities / Total Assets | 55.34 | 43.01 | 59.37 | 67.95 |
EBIT / Interest Expense | 83.36 | 12.78 | 3.16 | 3.13 |
EBITDA / Interest Expense | 91.16 | 20.58 | 4.98 | 5.12 |
(EBITDA - Capex) / Interest Expense | 86.13 | 17.25 | 4.04 | 4.02 |
Total Debt / EBITDA | 0.45 | 0.81 | 3.5 | 4.17 |
Net Debt / EBITDA | -1.3 | -3.7 | 0.52 | 2.41 |
Total Debt / (EBITDA - Capex) | 0.48 | 0.97 | 4.31 | 5.32 |
Net Debt / (EBITDA - Capex) | -1.38 | -4.42 | 0.65 | 3.07 |
Growth Over Prior Year | ||||
Total Revenues, 1 Yr. Growth % | - | 31.34 | 57.62 | 5.66 |
Gross Profit, 1 Yr. Growth % | - | -47.02 | 93.86 | 1.31 |
EBITDA, 1 Yr. Growth % | - | -46.69 | 56.71 | 11.54 |
EBITA, 1 Yr. Growth % | - | -58.33 | 72.4 | 11.58 |
EBIT, 1 Yr. Growth % | - | -61.31 | 73.77 | 16.25 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | -77.49 | 77.8 | 17.74 |
Net Income, 1 Yr. Growth % | - | -74.06 | 77.44 | 16.97 |
Normalized Net Income, 1 Yr. Growth % | - | -52.75 | 26.85 | 21.19 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | -74.59 | 60.28 | 16.97 |
Accounts Receivable, 1 Yr. Growth % | - | -7.97 | 24.57 | 16.15 |
Inventory, 1 Yr. Growth % | - | 23.48 | 59.66 | 19.68 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | -8.74 | 365.68 | 40.38 |
Total Assets, 1 Yr. Growth % | - | 16.88 | 72.41 | 17.68 |
Tangible Book Value, 1 Yr. Growth % | - | 71.46 | -5.14 | -48.21 |
Common Equity, 1 Yr. Growth % | - | 41.72 | 22.81 | -7.17 |
Cash From Operations, 1 Yr. Growth % | - | -39.54 | 64.4 | 16.83 |
Capital Expenditures, 1 Yr. Growth % | - | 68.98 | 99.13 | 20.75 |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | 92.74 | -6.62 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | 124.57 | -4.79 |
Dividend Per Share, 1 Yr. Growth % | - | - | - | 74.94 |
Compound Annual Growth Rate Over Two Years | ||||
Total Revenues, 2 Yr. CAGR % | - | - | 43.88 | 29.05 |
Gross Profit, 2 Yr. CAGR % | - | - | 17.22 | 40.25 |
EBITDA, 2 Yr. CAGR % | - | - | -8.6 | 26.07 |
EBITA, 2 Yr. CAGR % | - | - | -15.25 | 30.8 |
EBIT, 2 Yr. CAGR % | - | - | -18 | 33.25 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | -36.73 | 44.69 |
Net Income, 2 Yr. CAGR % | - | - | -32.15 | 44.06 |
Normalized Net Income, 2 Yr. CAGR % | - | - | -22.58 | 23.57 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | -36.18 | 36.92 |
Accounts Receivable, 2 Yr. CAGR % | - | - | 50.18 | 20.04 |
Inventory, 2 Yr. CAGR % | - | - | 40.41 | 38.23 |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | 106.15 | 155.68 |
Total Assets, 2 Yr. CAGR % | - | - | 41.95 | 42.44 |
Tangible Book Value, 2 Yr. CAGR % | - | - | 27.53 | -29.91 |
Common Equity, 2 Yr. CAGR % | - | - | 31.92 | 6.77 |
Cash From Operations, 2 Yr. CAGR % | - | - | -0.27 | 39.51 |
Capital Expenditures, 2 Yr. CAGR % | - | - | 83.43 | 55.06 |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 29.42 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 41.97 |
Compound Annual Growth Rate Over Three Years | ||||
Total Revenues, 3 Yr. CAGR % | - | - | - | 29.81 |
Gross Profit, 3 Yr. CAGR % | - | - | - | 11.71 |
EBITDA, 3 Yr. CAGR % | - | - | - | -5.38 |
EBITA, 3 Yr. CAGR % | - | - | - | -10.67 |
EBIT, 3 Yr. CAGR % | - | - | - | -11.76 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | -22.18 |
Net Income, 3 Yr. CAGR % | - | - | - | -18.65 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | -10.31 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | -21.9 |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | 37.67 |
Inventory, 3 Yr. CAGR % | - | - | - | 33.13 |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | 81.37 |
Total Assets, 3 Yr. CAGR % | - | - | - | 33.35 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | -5.56 |
Common Equity, 3 Yr. CAGR % | - | - | - | 17.34 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 5.6 |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | 59.57 |
- Stock Market
- Stocks
- PUREHEALTH Stock
- Financials Pure Health Holding
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















